SAMSON Pins Most Muscle Pain Experienced With Statins on the Nocebo Effect

 Steve Stiles

November 15, 2020

A novel randomized trial taking on a vexing issue around one of the world's most commonly prescribed medications has concluded that frequently intolerable statin side effects, such as muscle weakness or pain, are almost entirely a nocebo effect, the placebo effect's darker cousin.

The many patients who report such symptoms while taking statins are indeed probably feeling them, but they are a result of taking the pills rather than any pharmacologic effects, conclude researchers based on their 60-patient study, Self-Assessment Method for Statin Side-effects or Nocebo (SAMSON).

"SAMSON leaves no doubt that patients really do get side effects from statin tablets, but what it shows us is that 90% of this symptomatic burden is elicited by placebo tablets too," said James P. Howard, MB, PhD, Imperial College London, United Kingdom, when presenting the results November 15 during the American Heart Association (AHA) Scientific Sessions 2020 virtual meeting. They were published simultaneously in the New England Journal of Medicine.

Studies have shown that in practice, "more than half of patients abandon statins completely within 2 years. And yet, in placebo-controlled trials, no more people stop statins than placebo," Howard said. "The most important message from SAMSON is that side effects from statin tablets are very real, but they are mainly caused by the act of taking the tablets, not by the statin that is contained within them."

Patients in the trial, all of whom had a history of dropping statins because of side effects, each took atorvastatin 20 mg/day, a placebo, or neither pill for 1 month, alternating the regimens in randomized order over 1 year so that each was followed a total of 4 months. They used a smartphone app to record the severity of any side effects, not necessarily just pain, on a scale of 0 to 100.

Symptom intensity scores averaged 16.3 for atorvastatin and 15.4 for placebo, for a nonsignificant difference, but only 8.0 for no-pill months (P < .001 compared to the statin or placebo).

Because such symptoms seem to be based on patient expectations from statin therapy, positive communication about what the drugs can achieve and how the next treatment steps are described can play a big role in their continued use.

For example, "Changing them to another statin is a very reasonable thing to do, but as soon as you start trying people on lower doses and working up, you're sort of telling them that you're expecting at some dose that they are going to get side effects," cautioned Howard at a media briefing on SAMSON.

"The most important thing is to explain the evidence, and what our expectations are, maybe be a bit more optimistic about statins, and tell them they're very unlikely to suffer from side effects," he explained, "because the nocebo effect can only really rear its head if the patients are expecting to feel worse — just like the placebo effect will only work if people are expecting to feel better."

Amit Khera, MD, who moderated the media briefing, said he always tells such patients, "Yes, 1 in 10 patients report having muscle ache. But first and foremost, 9 in 10 don't. The vast majority of patients don't get muscle aches. I think that's really an important part of the communication."

Now, after SAMSON, "I have an additional point that I'm going to tell them: out of the patients that get muscle aches, probably 90% of that is the anticipation of getting the statin, the nocebo effect," said Khera, who directs the preventive cardiology program at UT Southwestern Medical Center, Dallas, Texas.

The trial complements years of observational and randomized trial evidence that the nocebo effect drives most such statin symptoms, and SAMSON is another tool clinicians can use when discussing that evidence with patients, observed Jennifer G. Robinson, MD, MPH, who directs the Preventive Intervention Center at the University of Iowa, Iowa City, but isn't affiliated with the current study.

"But we also need to supplement that — not with a message that 'it's all in your head' or 'there's something wrong with you,' but switching it on its head," she said when interviewed. "Say, 'yes, it's easy for people to perceive that the pain might be due to the statin, but we can find a dose of statin that you can take to have these lifesaving benefits, because there's nothing better than a statin in terms of saving lives.'"

The best course is to "have an open conversation with someone prescribed the medication, especially in secondary prevention, and spend some time up front talking about it," agreed Salim S. Virani, MD, PhD, for theheart.org | Medscape Cardiology.

The conversation should include, for example, that "every medication has side effects associated with it, and this medication also has side effects. But understand that it is one of the few medications that lowers your risk of heart attacks, strokes, and your risk of dying," said Virani, of Baylor College of Medicine, Houston, Texas.

"Having that conversation up front, rather than trying to chase the issue when the patient comes back in 2 months saying, 'My muscles are aching, I'm having difficulty raising my arm or my leg.' " By then, Virani said, "I think you've already missed the boat, in terms of developing a rapport with the patient and that confidence they need to have with the treating clinician."

SAMSON and the earlier research confirm that the nocebo effect is a "prominent" component of statin therapy for many patients, but the 60-patient study demonstrated a greater nocebo effect than in some other larger trials, such a GAUSS-3, observed one of its leaders, Steven E. Nissen, MD, Cleveland Clinic, Ohio.

That trial enrolled more than 500 patients, "and it was done using very rigorous methods," Nissen said for theheart.org | Medscape Cardiology. But "it showed some of the same things. There were people who had real statin intolerance, that is adverse effects on atorvastatin but not on placebo; and there are a lot of people who had adverse effects on placebo and actually not on atorvastatin," he said.

"What both trials tell us is that there are clearly a very significant number of people who believe they're statin intolerant, but who can actually tolerate statins." So SAMSON "helps us to understand that it's a nocebo effect, but it doesn't solve the problem," Nissen said.

"What I do with these patients is try another statin, and reinforce with them that muscle-related adverse effects are relatively uncommon. Many of these people are secondary prevention patients, and we know a statin will have a huge effect on their morbidity and mortality going forward."

In practice, many patients who report adverse statin effects do so later than 2 weeks after starting therapy, "so these findings cannot be generalized to them," proposed Francine K. Welty, MD, PhD, Beth Israel Deaconess Medical Center, Boston, Massachusetts, as the invited discussant after Howard's presentation.

All 60 patients recruited for SAMSON had previously stopped taking a statin because of side effects that arose within 2 weeks of their first dose. That requirement was intended to boost chances that any further symptoms during the trial would arise within a month of starting each new round of pills, Howard said.

So the trial's results, Welty said, "are limited to those subjects who develop symptoms within 2 weeks of starting a statin."

Including only such patients may have created bias toward a nocebo effect, she said, because "non–drug-related side effects of medications are often greatest during the initial weeks of treatment and tend to abate over time." For example, "Metformin causes diarrhea and β-blockers cause fatigue, but subjects do adapt and generally tolerate them very well."

The patients, 25 women and 35 men, 90% of whom were white, received four pill bottles, each with a month's supply of atorvastatin, four bottles each with 1 month of placebo, and four empty bottles each, to be used double-blind for a month in randomized order.

Patients used the smartphone app to document their symptom scores, which ranged from 0 for no symptoms to 100 for symptoms that were the "worst imaginable," the published report notes. Patients who experienced symptoms so severe as to be intolerable could stop the 1-month regimen they were then following, with instructions to resume the regimens in order starting the next month.

Eleven patients were unable to complete all 12 one-month segments of the trial.

The study's overall "nocebo ratio" of 0.90 was calculated as the difference between symptom intensity scores on placebo and on no treatment divided by the difference between symptom intensity on the statin and on no treatment. The interpretation: 90% of the symptom burden felt by patients receiving atorvastatin was also felt during placebo use.

Thirty of the patients, contacted 6 months after the trial concluded, had resumed taking a statin, while "4 planned to do so and one could not be contacted," the report notes. The 25 other patients weren't receiving a statin and had no plans to take one.

In an important part of the trial, Howard said, at its conclusion the patients were shown their pattern of symptoms in relation to whether they were taking the statin, placebo, or neither. "Participants could see as clearly as we could the surprisingly powerful magnitude of the nocebo effect. And this led to half of our patients happily restarting statins."

The implications of SAMSON, Welty said, "are very important, in that those developing symptoms within 2 weeks of starting a statin should be reassured that approximately half will be able to successful restart the statin."

SAMSON was funded by the British Heart Foundation. Howard had no disclosures. Welty discloses chairing the data safety monitoring committee for Empagliflozin International Clinical Trials, supported by Boehringer Ingelheim.

Khera had no disclosures. Virani reports receiving honoraria from the American College of Cardiology as an Associate Editor for Innovations. Robinson has previously disclosed receiving institutional grants from Acasti, Amarin, Amgen, Astra-Zeneca, Esai, Esperion, Merck, Pfizer, Regeneron, Sanofi, Takeda, The Medicines Company, Novartis, and Novo Nordisk; and serving as a consultant for Amgen, The Medicines Company, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron and Sanofi. Nissen reports that his center has received funding for clinical trials from AbbVie, AstraZeneca, Amgen, Cerenis, Eli Lilly, Esperion, Medtronic, MyoKardia, Novartis, Pfizer, The Medicines Company, Silence Therapeutics, Takeda, and Orexigen; that he is involved in these trials but receives no personal remuneration; and that he consults for many pharmaceutical companies but requires them to donate all honoraria or fees directly to charity so that he receives neither income nor a tax deduction.

American Heart Association Scientific Sessions 2020. LBS.04. Presented November 15, 2020.

N Engl J Med. November 15, 2020. Abstract

Follow Steve Stiles on Twitter: @SteveStiles2. For more from theheart.org | Medscape Cardiology, follow us on Twitter and Facebook.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....